Advanced Biomed Inc. Common Stock (ADVB) is a Healthcare stock trading at $9.60 (as of 2026-09-02), with a market capitalization of $13.27M and a trailing P/E of 3.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also provides microfluidic biochips comprising A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips that are designed to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include the A+CTCE kit, which is used to identify epithelial circulating tumor cells and is determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; the A+CTCM kit, which is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; the A+EMT, which is used to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and the A+CM, which is used to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Advanced Biomed develops microfluidic biochip devices (A+Pre, AC-1000, A+SCDrop, A+CellScan) for precision oncology detection and treatment, sold to clinical labs in Taiwan. The holding company sits in the pre-revenue stage of commercializing its chip-based cancer screening platform, with no meaningful top-line yet to underwrite.
Revenue is effectively zero, so the 76,061% operating margin is a pure denominator artifact; the real moat question is whether any of the four biochip devices clears regulatory approval and generates sustained lab demand.
Business quality (Unprofitable): Graded Unprofitable with no citable revenue; the 76,061% operating margin is a mathematical byproduct of a near-zero denominator, not evidence of operational excellence.
| Price | $9.60 |
| Market Cap | $13.27M |
| P/E Ratio | 3.2 |
| EV / EBITDA | 2.1 |
| Price / Book | 1.44 |
| Price / Sales | 327.83 |
| FCF Yield | -44.1% |
| Revenue (TTM) | $24915.00 |
| Net Margin | -13080.3% |
| Revenue Growth (YoY) | -40.3% |
| EPS Growth (YoY) | -875.0% |
| FCF Growth (YoY) | 23.6% |
| Altman Z-Score | 39.38 (safe) |
| Stock P/E | 3.2 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Healthcare Services) | 24.6 |
| vs Sector | -85.3% |
| vs Industry | -87.1% |
| Top Institutional Holder | CITADEL ADVISORS LLC ($62515.00) |
| Institutional Holders Tracked | 5 |
| Sector | Healthcare |
| Industry | Healthcare Services |
| CEO | Yi Lu |
| Employees | 40 |
| Country | US |
| IPO Date | 2025-03-06 |
Data as of 2026-09-02.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.